Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials

A. Michael Lincoff; Leroy A. Lenarz; George J. Despotis; Peter K. Smith; Joan E. Booth; Russell E. Raymond; Shelly K. Sapp; Catherine F. Cabot; James E. Tcheng; Robert M. Califf; Mark B. Effron; Eric J. Topol; Dean J. Kereiakes; John Paul Runyon; Thomas Kelly; George Timmis; Neal S. Kleiman; Jeffrey Kramer; David Talley; Frank I. Navetta; Phillip Kraft; James Ferguson; Kevin Browne; James Blankenship; Russell Ivanhoe; Neal Shadoff; Mark Taylor; Gerald Gacioch; Eric Bates; H. A. Snyder; Theodore A. Bass; Philip Bear; Larry Hattel; H. Vernon Anderson; Bruce Hettleman; Paul S. Teirstein; Ian Sarembock; Charles J. Davidson; Frank V. Aguirre; Michael Azrin; Seth Worley; Jean Francois Marquis; Douglas J. Spriggs; Mark W. Weston; Barry S. George; Donald R. Ricci; Carl W. Hartman; Anthony Farah; Gary Sander; Bernard M. Reen; Richard Heuser; Timothy Larkin; Jeffrey Popma; Mark L. Sanz; Jeffrey Burton; Robert I.G. Brown; William J. French; Allan G. Adelman; Ronald Gottlieb; Spencer B. King; John Ducas; Judith S. Hochman; Blair J. O'Neill; Po Kee Cheung; Merril Knudtson; Joseph Samaha; Lloyd W. Klein; David Almond; Michael J. Rosenberg; Michael Unks; Eric Cohen; John C. Webb; Jean Francois Tanguay; Patrick S. Coleman; Mark Thompson; Alan Gradman; Steven Yakubov; Mark Tannenbaum; Mark Gonzalez; Richard Bach; Frank E. Cummins; Charles Lucore; Brent Muhlestein; Robert Chisholm; Michael Del Core

doi:10.1016/S0003-4975(00)01343-6

Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials

A. Michael Lincoff^*, Leroy A. Lenarz, George J. Despotis, Peter K. Smith, Joan E. Booth, Russell E. Raymond, Shelly K. Sapp, Catherine F. Cabot, James E. Tcheng, Robert M. Califf, Mark B. Effron, Eric J. Topol, Dean J. Kereiakes, John Paul Runyon, Thomas Kelly, George Timmis, Neal S. Kleiman, Jeffrey Kramer, David Talley, Frank I. NavettaPhillip Kraft, James Ferguson, Kevin Browne, James Blankenship, Russell Ivanhoe, Neal Shadoff, Mark Taylor, Gerald Gacioch, Eric Bates, H. A. Snyder, Theodore A. Bass, Philip Bear, Larry Hattel, H. Vernon Anderson, Bruce Hettleman, Paul S. Teirstein, Ian Sarembock, Charles J. Davidson, Frank V. Aguirre, Michael Azrin, Seth Worley, Jean Francois Marquis, Douglas J. Spriggs, Mark W. Weston, Barry S. George, Donald R. Ricci, Carl W. Hartman, Anthony Farah, Gary Sander, Bernard M. Reen, Richard Heuser, Timothy Larkin, Jeffrey Popma, Mark L. Sanz, Jeffrey Burton, Robert I.G. Brown, William J. French, Allan G. Adelman, Ronald Gottlieb, Spencer B. King, John Ducas, Judith S. Hochman, Blair J. O'Neill, Po Kee Cheung, Merril Knudtson, Joseph Samaha, Lloyd W. Klein, David Almond, Michael J. Rosenberg, Michael Unks, Eric Cohen, John C. Webb, Jean Francois Tanguay, Patrick S. Coleman, Mark Thompson, Alan Gradman, Steven Yakubov, Mark Tannenbaum, Mark Gonzalez, Richard Bach, Frank E. Cummins, Charles Lucore, Brent Muhlestein, Robert Chisholm, Michael Del Core

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. Methods. Outcomes were assessed among 85 patients who required coronary artery bypass grafting operations after coronary intervention in two randomized placebo-controlled trials of abciximab. Comparisons were made between patients in the pooled placebo and abciximab groups. Results. The incidence of coronary surgical procedures was 2.17% and 1.28% among patients randomized to placebo and abciximab, respectively (p = 0.021). Platelet transfusions were administered to 32% and 52% of patients in the placebo and abciximab groups, respectively (p = 0.059). Rates of major blood loss were 79% and 88% in the placebo and abciximab groups, respectively (p = 0.27); transfusions of packed red blood cells or whole blood were administered in 74% and 80% of patients, respectively (p = 0.53). Surgical reexploration for bleeding was required in 3% and 12% of patients, respectively. Death and myocardial infarction tended to occur less frequently among patients who had received abciximab. Conclusions. Urgent coronary artery bypass grafting operations can be performed without an incremental increase in major hemorrhagic risk among patients on abciximab therapy. (C) 2000 by The Society of Thoracic Surgeons.

Original language	English (US)
Pages (from-to)	516-526
Number of pages	11
Journal	Annals of Thoracic Surgery
Volume	70
Issue number	2
DOIs	https://doi.org/10.1016/S0003-4975(00)01343-6
State	Published - 2000

Funding

Supported by Eli Lilly and Company (Indianapolis, IN) and Centocor, Inc (Malvern, PA).

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0003-4975(00)01343-6

Cite this

Lincoff, A. M., Lenarz, L. A., Despotis, G. J., Smith, P. K., Booth, J. E., Raymond, R. E., Sapp, S. K., Cabot, C. F., Tcheng, J. E., Califf, R. M., Effron, M. B., Topol, E. J., Kereiakes, D. J., Runyon, J. P., Kelly, T., Timmis, G., Kleiman, N. S., Kramer, J., Talley, D., ... Del Core, M. (2000). Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Annals of Thoracic Surgery, 70(2), 516-526. https://doi.org/10.1016/S0003-4975(00)01343-6

@article{8e58fd87f7cb41fd88b090451ab4c804,

title = "Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials",

abstract = "Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. Methods. Outcomes were assessed among 85 patients who required coronary artery bypass grafting operations after coronary intervention in two randomized placebo-controlled trials of abciximab. Comparisons were made between patients in the pooled placebo and abciximab groups. Results. The incidence of coronary surgical procedures was 2.17% and 1.28% among patients randomized to placebo and abciximab, respectively (p = 0.021). Platelet transfusions were administered to 32% and 52% of patients in the placebo and abciximab groups, respectively (p = 0.059). Rates of major blood loss were 79% and 88% in the placebo and abciximab groups, respectively (p = 0.27); transfusions of packed red blood cells or whole blood were administered in 74% and 80% of patients, respectively (p = 0.53). Surgical reexploration for bleeding was required in 3% and 12% of patients, respectively. Death and myocardial infarction tended to occur less frequently among patients who had received abciximab. Conclusions. Urgent coronary artery bypass grafting operations can be performed without an incremental increase in major hemorrhagic risk among patients on abciximab therapy. (C) 2000 by The Society of Thoracic Surgeons.",

author = "Lincoff, {A. Michael} and Lenarz, {Leroy A.} and Despotis, {George J.} and Smith, {Peter K.} and Booth, {Joan E.} and Raymond, {Russell E.} and Sapp, {Shelly K.} and Cabot, {Catherine F.} and Tcheng, {James E.} and Califf, {Robert M.} and Effron, {Mark B.} and Topol, {Eric J.} and Kereiakes, {Dean J.} and Runyon, {John Paul} and Thomas Kelly and George Timmis and Kleiman, {Neal S.} and Jeffrey Kramer and David Talley and Navetta, {Frank I.} and Phillip Kraft and James Ferguson and Kevin Browne and James Blankenship and Russell Ivanhoe and Neal Shadoff and Mark Taylor and Gerald Gacioch and Eric Bates and Snyder, {H. A.} and Bass, {Theodore A.} and Philip Bear and Larry Hattel and Anderson, {H. Vernon} and Bruce Hettleman and Teirstein, {Paul S.} and Ian Sarembock and Davidson, {Charles J.} and Aguirre, {Frank V.} and Michael Azrin and Seth Worley and Marquis, {Jean Francois} and Spriggs, {Douglas J.} and Weston, {Mark W.} and George, {Barry S.} and Ricci, {Donald R.} and Hartman, {Carl W.} and Anthony Farah and Gary Sander and Reen, {Bernard M.} and Richard Heuser and Timothy Larkin and Jeffrey Popma and Sanz, {Mark L.} and Jeffrey Burton and Brown, {Robert I.G.} and French, {William J.} and Adelman, {Allan G.} and Ronald Gottlieb and King, {Spencer B.} and John Ducas and Hochman, {Judith S.} and O'Neill, {Blair J.} and Cheung, {Po Kee} and Merril Knudtson and Joseph Samaha and Klein, {Lloyd W.} and David Almond and Rosenberg, {Michael J.} and Michael Unks and Eric Cohen and Webb, {John C.} and Tanguay, {Jean Francois} and Coleman, {Patrick S.} and Mark Thompson and Alan Gradman and Steven Yakubov and Mark Tannenbaum and Mark Gonzalez and Richard Bach and Cummins, {Frank E.} and Charles Lucore and Brent Muhlestein and Robert Chisholm and {Del Core}, Michael",

note = "Funding Information: Supported by Eli Lilly and Company (Indianapolis, IN) and Centocor, Inc (Malvern, PA). ",

year = "2000",

doi = "10.1016/S0003-4975(00)01343-6",

language = "English (US)",

volume = "70",

pages = "516--526",

journal = "Annals of Thoracic Surgery",

issn = "0003-4975",

publisher = "Elsevier Inc.",

number = "2",

}

Lincoff, AM, Lenarz, LA, Despotis, GJ, Smith, PK, Booth, JE, Raymond, RE, Sapp, SK, Cabot, CF, Tcheng, JE, Califf, RM, Effron, MB, Topol, EJ, Kereiakes, DJ, Runyon, JP, Kelly, T, Timmis, G, Kleiman, NS, Kramer, J, Talley, D, Navetta, FI, Kraft, P, Ferguson, J, Browne, K, Blankenship, J, Ivanhoe, R, Shadoff, N, Taylor, M, Gacioch, G, Bates, E, Snyder, HA, Bass, TA, Bear, P, Hattel, L, Anderson, HV, Hettleman, B, Teirstein, PS, Sarembock, I, Davidson, CJ, Aguirre, FV, Azrin, M, Worley, S, Marquis, JF, Spriggs, DJ, Weston, MW, George, BS, Ricci, DR, Hartman, CW, Farah, A, Sander, G, Reen, BM, Heuser, R, Larkin, T, Popma, J, Sanz, ML, Burton, J, Brown, RIG, French, WJ, Adelman, AG, Gottlieb, R, King, SB, Ducas, J, Hochman, JS, O'Neill, BJ, Cheung, PK, Knudtson, M, Samaha, J, Klein, LW, Almond, D, Rosenberg, MJ, Unks, M, Cohen, E, Webb, JC, Tanguay, JF, Coleman, PS, Thompson, M, Gradman, A, Yakubov, S, Tannenbaum, M, Gonzalez, M, Bach, R, Cummins, FE, Lucore, C, Muhlestein, B, Chisholm, R & Del Core, M 2000, 'Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials', Annals of Thoracic Surgery, vol. 70, no. 2, pp. 516-526. https://doi.org/10.1016/S0003-4975(00)01343-6

TY - JOUR

T1 - Abciximab and bleeding during coronary surgery

T2 - Results from the EPILOG and EPISTENT trials

AU - Lincoff, A. Michael

AU - Lenarz, Leroy A.

AU - Despotis, George J.

AU - Smith, Peter K.

AU - Booth, Joan E.

AU - Raymond, Russell E.

AU - Sapp, Shelly K.

AU - Cabot, Catherine F.

AU - Tcheng, James E.

AU - Califf, Robert M.

AU - Effron, Mark B.

AU - Topol, Eric J.

AU - Kereiakes, Dean J.

AU - Runyon, John Paul

AU - Kelly, Thomas

AU - Timmis, George

AU - Kleiman, Neal S.

AU - Kramer, Jeffrey

AU - Talley, David

AU - Navetta, Frank I.

AU - Kraft, Phillip

AU - Ferguson, James

AU - Browne, Kevin

AU - Blankenship, James

AU - Ivanhoe, Russell

AU - Shadoff, Neal

AU - Taylor, Mark

AU - Gacioch, Gerald

AU - Bates, Eric

AU - Snyder, H. A.

AU - Bass, Theodore A.

AU - Bear, Philip

AU - Hattel, Larry

AU - Anderson, H. Vernon

AU - Hettleman, Bruce

AU - Teirstein, Paul S.

AU - Sarembock, Ian

AU - Davidson, Charles J.

AU - Aguirre, Frank V.

AU - Azrin, Michael

AU - Worley, Seth

AU - Marquis, Jean Francois

AU - Spriggs, Douglas J.

AU - Weston, Mark W.

AU - George, Barry S.

AU - Ricci, Donald R.

AU - Hartman, Carl W.

AU - Farah, Anthony

AU - Sander, Gary

AU - Reen, Bernard M.

AU - Heuser, Richard

AU - Larkin, Timothy

AU - Popma, Jeffrey

AU - Sanz, Mark L.

AU - Burton, Jeffrey

AU - Brown, Robert I.G.

AU - French, William J.

AU - Adelman, Allan G.

AU - Gottlieb, Ronald

AU - King, Spencer B.

AU - Ducas, John

AU - Hochman, Judith S.

AU - O'Neill, Blair J.

AU - Cheung, Po Kee

AU - Knudtson, Merril

AU - Samaha, Joseph

AU - Klein, Lloyd W.

AU - Almond, David

AU - Rosenberg, Michael J.

AU - Unks, Michael

AU - Cohen, Eric

AU - Webb, John C.

AU - Tanguay, Jean Francois

AU - Coleman, Patrick S.

AU - Thompson, Mark

AU - Gradman, Alan

AU - Yakubov, Steven

AU - Tannenbaum, Mark

AU - Gonzalez, Mark

AU - Bach, Richard

AU - Cummins, Frank E.

AU - Lucore, Charles

AU - Muhlestein, Brent

AU - Chisholm, Robert

AU - Del Core, Michael

N1 - Funding Information: Supported by Eli Lilly and Company (Indianapolis, IN) and Centocor, Inc (Malvern, PA).

PY - 2000

Y1 - 2000

N2 - Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. Methods. Outcomes were assessed among 85 patients who required coronary artery bypass grafting operations after coronary intervention in two randomized placebo-controlled trials of abciximab. Comparisons were made between patients in the pooled placebo and abciximab groups. Results. The incidence of coronary surgical procedures was 2.17% and 1.28% among patients randomized to placebo and abciximab, respectively (p = 0.021). Platelet transfusions were administered to 32% and 52% of patients in the placebo and abciximab groups, respectively (p = 0.059). Rates of major blood loss were 79% and 88% in the placebo and abciximab groups, respectively (p = 0.27); transfusions of packed red blood cells or whole blood were administered in 74% and 80% of patients, respectively (p = 0.53). Surgical reexploration for bleeding was required in 3% and 12% of patients, respectively. Death and myocardial infarction tended to occur less frequently among patients who had received abciximab. Conclusions. Urgent coronary artery bypass grafting operations can be performed without an incremental increase in major hemorrhagic risk among patients on abciximab therapy. (C) 2000 by The Society of Thoracic Surgeons.

AB - Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. Methods. Outcomes were assessed among 85 patients who required coronary artery bypass grafting operations after coronary intervention in two randomized placebo-controlled trials of abciximab. Comparisons were made between patients in the pooled placebo and abciximab groups. Results. The incidence of coronary surgical procedures was 2.17% and 1.28% among patients randomized to placebo and abciximab, respectively (p = 0.021). Platelet transfusions were administered to 32% and 52% of patients in the placebo and abciximab groups, respectively (p = 0.059). Rates of major blood loss were 79% and 88% in the placebo and abciximab groups, respectively (p = 0.27); transfusions of packed red blood cells or whole blood were administered in 74% and 80% of patients, respectively (p = 0.53). Surgical reexploration for bleeding was required in 3% and 12% of patients, respectively. Death and myocardial infarction tended to occur less frequently among patients who had received abciximab. Conclusions. Urgent coronary artery bypass grafting operations can be performed without an incremental increase in major hemorrhagic risk among patients on abciximab therapy. (C) 2000 by The Society of Thoracic Surgeons.

UR - http://www.scopus.com/inward/record.url?scp=0033836321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033836321&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(00)01343-6

DO - 10.1016/S0003-4975(00)01343-6

M3 - Article

C2 - 10969673

AN - SCOPUS:0033836321

SN - 0003-4975

VL - 70

SP - 516

EP - 526

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

IS - 2

ER -

Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this